
Andrew W. Sutton
Examiner (ID: 2699, Phone: (571)272-6093 , Office: P/3765 )
| Most Active Art Unit | 3765 |
| Art Unit(s) | 3765, 3732 |
| Total Applications | 970 |
| Issued Applications | 523 |
| Pending Applications | 21 |
| Abandoned Applications | 428 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17140082
[patent_doc_number] => 20210308093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => ACTIVATOR FOR SIMULTANEOUSLY ACTIVATING OXIDATIVE PHOSPHORYLATION AND INHIBITING GLYCOLYSIS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/261430
[patent_app_country] => US
[patent_app_date] => 2020-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2944
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17261430
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/261430 | ACTIVATOR FOR SIMULTANEOUSLY ACTIVATING OXIDATIVE PHOSPHORYLATION AND INHIBITING GLYCOLYSIS AND USE THEREOF | Jun 27, 2020 | Abandoned |
Array
(
[id] => 18057899
[patent_doc_number] => 20220388985
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/619459
[patent_app_country] => US
[patent_app_date] => 2020-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17640
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -58
[patent_words_short_claim] => 1249
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17619459
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/619459 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Jun 17, 2020 | Abandoned |
Array
(
[id] => 17896975
[patent_doc_number] => 20220306637
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => Imidazopyrazine Derivatives and the Use Thereof as Medicament
[patent_app_type] => utility
[patent_app_number] => 17/616205
[patent_app_country] => US
[patent_app_date] => 2020-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5825
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616205
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/616205 | Imidazopyrazine derivatives and the use thereof as medicament | Jun 2, 2020 | Issued |
Array
(
[id] => 17355280
[patent_doc_number] => 20220016076
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN
[patent_app_type] => utility
[patent_app_number] => 16/890722
[patent_app_country] => US
[patent_app_date] => 2020-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19088
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16890722
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/890722 | SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN | Jun 1, 2020 | Abandoned |
Array
(
[id] => 17720380
[patent_doc_number] => 20220213100
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/614652
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37345
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614652
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/614652 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | May 28, 2020 | Issued |
Array
(
[id] => 17761393
[patent_doc_number] => 20220235005
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => FUNGICIDAL N-(PYRID-3-YL)CARBOXAMIDES
[patent_app_type] => utility
[patent_app_number] => 17/608497
[patent_app_country] => US
[patent_app_date] => 2020-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45973
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 1599
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608497
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/608497 | FUNGICIDAL N-(PYRID-3-YL)CARBOXAMIDES | May 25, 2020 | Abandoned |
Array
(
[id] => 17945682
[patent_doc_number] => 20220332699
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/613870
[patent_app_country] => US
[patent_app_date] => 2020-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59712
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613870
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/613870 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | May 23, 2020 | Pending |
Array
(
[id] => 17749531
[patent_doc_number] => 20220227735
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => THERAPEUTIC METHODS AND COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/605732
[patent_app_country] => US
[patent_app_date] => 2020-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20473
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605732
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605732 | THERAPEUTIC METHODS AND COMPOUNDS | Apr 21, 2020 | Pending |
Array
(
[id] => 17719009
[patent_doc_number] => 20220211728
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => ALKYL-TPP COMPOUNDS FOR MITOCHONDRIA TARGETING AND ANTI-CANCER TREATMENTS
[patent_app_type] => utility
[patent_app_number] => 17/604651
[patent_app_country] => US
[patent_app_date] => 2020-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9654
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604651
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/604651 | ALKYL-TPP COMPOUNDS FOR MITOCHONDRIA TARGETING AND ANTI-CANCER TREATMENTS | Apr 15, 2020 | Pending |
Array
(
[id] => 17656960
[patent_doc_number] => 20220177425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => SMALL MOLECULES FOR CANCER THERAPY THAT REDUCE THE EXPRESSION OF TRANSCRIPTION FACTORS KLF5 AND EGR-1
[patent_app_type] => utility
[patent_app_number] => 17/602924
[patent_app_country] => US
[patent_app_date] => 2020-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12786
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 183
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602924
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602924 | Small molecules for cancer therapy that reduce the expression of transcription factors KLF5 and EGR-1 | Apr 9, 2020 | Issued |
Array
(
[id] => 17596918
[patent_doc_number] => 20220146492
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => CELL MEMBRANE PERMEABILITY RESTORING THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/602136
[patent_app_country] => US
[patent_app_date] => 2020-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -61
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602136
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602136 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Apr 9, 2020 | Pending |
Array
(
[id] => 17702768
[patent_doc_number] => 20220202774
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SPINAL CORD INJURY OR SPINAL STENOSIS
[patent_app_type] => utility
[patent_app_number] => 17/594889
[patent_app_country] => US
[patent_app_date] => 2020-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6793
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594889
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/594889 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SPINAL CORD INJURY OR SPINAL STENOSIS | Apr 6, 2020 | Abandoned |
Array
(
[id] => 17685728
[patent_doc_number] => 20220193020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => Pharmaceutical Composition Comprising Trimebutine or Pharmaceutically Acceptable Salt Thereof as an Active Ingredient For Prevention or Treatment of Cancer
[patent_app_type] => utility
[patent_app_number] => 17/600976
[patent_app_country] => US
[patent_app_date] => 2020-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8105
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600976
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/600976 | Pharmaceutical composition comprising trimebutine or pharmaceutically acceptable salt thereof as an active ingredient for prevention or treatment of cancer | Apr 5, 2020 | Issued |
Array
(
[id] => 17609765
[patent_doc_number] => 20220152044
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM
[patent_app_type] => utility
[patent_app_number] => 17/593249
[patent_app_country] => US
[patent_app_date] => 2020-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9926
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17593249
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/593249 | TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM | Mar 15, 2020 | Pending |
Array
(
[id] => 20187036
[patent_doc_number] => 12398141
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-26
[patent_title] => JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine
[patent_app_type] => utility
[patent_app_number] => 17/437944
[patent_app_country] => US
[patent_app_date] => 2020-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28684
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 299
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17437944
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/437944 | JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine | Mar 10, 2020 | Issued |
Array
(
[id] => 20372394
[patent_doc_number] => 12479816
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-25
[patent_title] => 20-HETE formation inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/429289
[patent_app_country] => US
[patent_app_date] => 2020-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54463
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429289
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/429289 | 20-HETE formation inhibitors | Feb 6, 2020 | Issued |
Array
(
[id] => 18165640
[patent_doc_number] => 20230032239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-02
[patent_title] => A METHOD OF TREATMENT IN PREDISPOSED SUBJECTS FOR LMNA-RELATED DILATED CARDIOMYOPATHY
[patent_app_type] => utility
[patent_app_number] => 17/791110
[patent_app_country] => US
[patent_app_date] => 2020-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7610
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791110
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/791110 | A METHOD OF TREATMENT IN PREDISPOSED SUBJECTS FOR LMNA-RELATED DILATED CARDIOMYOPATHY | Jan 14, 2020 | Pending |
Array
(
[id] => 17428344
[patent_doc_number] => 20220056052
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/415584
[patent_app_country] => US
[patent_app_date] => 2019-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25540
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 469
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17415584
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/415584 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | Dec 26, 2019 | Pending |
Array
(
[id] => 17443654
[patent_doc_number] => 20220064159
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => BICYCLIC DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/415309
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 1677
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17415309
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/415309 | BICYCLIC DERIVATIVES | Dec 12, 2019 | Abandoned |
Array
(
[id] => 19042281
[patent_doc_number] => 11931354
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-19
[patent_title] => Formulations of oxabicycloheptanes and oxabicycloheptenes
[patent_app_type] => utility
[patent_app_number] => 16/705699
[patent_app_country] => US
[patent_app_date] => 2019-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 11534
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16705699
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/705699 | Formulations of oxabicycloheptanes and oxabicycloheptenes | Dec 5, 2019 | Issued |